Elena Wolff-Holz, MD, discussed the approval and benefits of the ustekinumab biosimilar, Yesintek, emphasizing its comparable efficacy and safety to Stelara, and potential for increased patient access ...

Number 5: The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed ...

Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, ...

The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed key ...

It is time for the agency to start thinking like an innovator, not an impediment to innovation. By modernizing and ...

A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for ...

To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and ...

Between congressional hearings and executive orders, experts had plenty to draw on when dissecting the barriers to biosimilar ...

Number 5: Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for ...

Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...

Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of ...